Forms of rifaximin and uses thereof
AssigneeSalix Pharmaceuticals, Inc.
InventorsKaren S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
Life of this patent
Estimating the term…
Abstract
The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
Claims19
A rifaximin polymorph Form ζ, wherein the polymorphic Form ζ exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree θ) comprising:
- 4.69, 7.63, 12.52, and 13.87;
- 4.69, 7.63 and 12.52;
- 4.69, 7.63 and 13.87;
- 4.69, 12.52 and 13.87;
- or
- 7.63, 12.52 and 13.87.
A rifaximin polymorph Form η, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree θ) comprising:
- 6.1, 7.3, and 7.5;
- 6.1, 7.3, and 7.9;
- 6.1, 7.3 and 8.8;
- 6.1, 7.3 and 12.7;
- 6.1, 7.5 and 7.9;
- 6.1, 7.5 and 8.8;
- 5.3, 6.1 and 7.3;
- 5.3, 6.1 and 7.5;
- 6.1, 7.3, 7.5, 7.9, 8.8 and 12.7;
- 5.3, 6.1, 7.3, 7.9, 8.8 and 12.7;
- 5.3, 6.1, 7.3, 7.5, 8.8, and 12.7;
- or
- 5.3, 6.1, 7.3, 7.5, 7.9, 8.8 and 12.7.
A rifaximin polymorph Form ι, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree θ) comprising:
- 5.49, 5.88, 7.86, 9.03, 12.66, and 13.89;
- 5.49, 5.88, 7.86, 9.03, and 12.66;
- 5.49, 5.88, 9.03, 12.66 and 13.89;
- 5.49, 7.86, 9.03, 12.66 and 13.89;
- 5.49, 5.88, 7.86, 9.03 and 13.89;
- 5.88, 7.86, 9.03, 12.66 and 13.89;
- 5.9, 7.9, and 9.0;
- 12.7, 13.9, and 14.9;
- 5.9, 7.9, and 12.7;
- 5.9, 9.0, and 12.7;
- 5.9, 13.9, and 14.9;
- 5.9, 7.9, and 14.9;
- 7.4, 20.0 and 20.9;
- 9.0, 12.7, and 14.9;
- 20.0, 20.9 and 23.4;
- 5.9, 7.9, 9.0, and 14.9;
- 5.9, 7.9, 9.0, and 12.7;
- 5.9, 7.4, 7.9 and 9.4;
- 7.4, 12.7, 13.9 and 23.4;
- 5.9, 13.9, 14.9, 20.0 and 20.9;
- 5.9, 7.9, 9.0, 12.7, 13.9, and 14.9;
- 5.9, 7.4, 7.9, 12.7, 13.9, 14.9, 20.0, 20.9 and 23.4;
- or
- 5.9, 7.4, 7.9, 9.0, 9.4, 12.7, 13.9, 14.9, 20.0, 20.9 and 23.4.
A rifaximin polymorph Form ι-dry, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree θ) comprising:
- 6.04, 7.90, 8.92, 9.49, 12.76, and 14.14;
- 6.04, 8.92, 9.49, 12.76 and 14.14;
- 6.04, 7.90, 9.49, 12.76 and 14.14;
- 6.04, 7.90, 8.92, 9.49 and 14.14;
- 6.04, 7.90, 8.92, 9.49 and 12.76;
- 6.04, 7.90, 8.92, 12.76 and 14.14;
- or
- 7.90, 8.92, 9.49, 12.76, and 14.14.
A rifaximin polymorph Form ι-dry′, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree θ) comprising:
- 6.16, 7.92, 8.89, 9.55, 12.80, and 14.25;
- 6.16, 8.89, 9.55, 12.80 and 14.25;
- 6.16, 7.92, 9.55, 12.80 and 14.25;
- 6.16, 7.92, 8.89, 12.80 and 14.25;
- 6.16, 7.92, 8.89, 9.55 and 14.25;
- 6.16, 7.92, 8.89, 9.55 and 12.80;
- or
- 7.92, 8.89, 9.55, 12.80 and 14.25.
A rifaximin polymorph Form B, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree θ) comprising:
- 5.24, 6.84, 7.74, 8.71, 10.16, and 12.21;
- 5.24, 7.74, 8.71, 10.16 and 12.21;
- 5.24, 6.84, 8.71, 10.16 and 12.21;
- 5.24, 6.84, 7.74, 10.16 and 12.21;
- 5.24, 6.84, 7.74, 8.71 and 12.21;
- 5.24, 6.84, 7.74, 8.71 and 10.16;
- 6.84, 7.74, 8.71, 10.16 and 12.21;
- or
- 5.24, 6.84 and 7.74.
Dependencies are inferred from the claim text.